本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
DONGGUAN, China and PLANO, Texas, May 19, 2025 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that the Company has entered into a share acquisition agreement (the "Agreement") with a shareholder of Dogness Intelligent Technology Co., Ltd. ("DITC") to acquire a 19.5% equity interest in DITC in exchange for Dogness's Class A common shares and warrants to purchase Class A common shares. Established in 2018, DITC focuses on the research and development of Internet of Things (IoT) and app platforms in the pet industry. DITC is dedicated to creating user-centered intelligent petcare devices and applications that help track pet activities, collect health data, protect, feed, follow, and monitor pets, even if owners are not with their pets. Mr. Silong Chen, Chief Executive Officer of Dogness, stated, "We are pleased to invest and acquire a strategic stake in DITC, an emerging player in petcare technology. With the growing focus on pet health and wellness, and advancements in IoT, AI, and data analytics driving demand for pet tech products that monitor activity and track vitals, DITC's innovative approach and commitment to developing a user-centered intelligent pet ecosystem align well with our strategic goals. We are excited to work with DITC and explore new opportunities for growth in the expanding petcare market." For further information regarding this transaction, please see the Form 6-K to be filed with the SEC. About Dogness Dogness (International) Corporation was founded in 2003 from the belief that pet dogs and cats are important, well-loved family members. Through its smart products, hygiene products, health and wellness products, and leash products, Dogness is able to simplify pet lifestyles, make them more scientific, and enhance the relationship between pets and pet caregivers. The Company ensures industry-leading quality through its fully integrated vertical supply chain and world-class research and development capabilities, which has resulted in over 200 patents and patents pending. Dogness products reach families worldwide through global chain stores and distributors. For more information, please visit: ir.dogness.com. Forward Looking Statements No statement made in this press release should be interpreted as an offer to purchase or sell any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Certain statements in this press release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the "safe harbor" under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding lingering effects of the Covid-19 pandemic on our customers' businesses and end purchasers' disposable income, our ability to raise capital on any particular terms, fulfillment of customer orders, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, our ability to realize revenue from expanded operation and acquired assets in China and the U.S., our ability to attract and retain highly skilled professionals, client concentration, industry segment concentration, reduced demand for technology in our key focus areas, our ability to successfully complete and integrate potential acquisitions, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings. These filings are available at www.sec.gov. Dogness may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date of this press release. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law. For more information please contact: Wealth Financial Services LLCConnie Kang, PartnerEmail: ckang@wealthfsllc.comTel: +86 1381 185 7742 (CN)
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced major milestones in the United States, one year after its acquisition of Volpara Health Technologies. Since acquiring Volpara, Lunit has significantly expanded its presence across North America. By June 2025, Lunit's AI solutions for digital breast tomosynthesis (Lunit INSIGHT DBT) and mammography analysis (Lunit INSIGHT MMG) will be deployed at over 200 imaging centers and hospitals across the U.S., with approximately 350 to 400 radiologists utilizing its technology. Together, Lunit and Volpara now power more than one million annual mammograms across North America — a major step forward in the company's U.S. growth strategy. Lunit's growing customer base includes leading healthcare providers such as Rezolut, SimonMed Imaging, and UC Davis Health, reflecting its strengthening position in the U.S. medical imaging market. In addition to its expanding U.S. footprint, Lunit and Volpara introduced the concept of a comprehensive Ecosystem for Cancer Detection and Care at RSNA 2024. The Ecosystem is designed to unify AI technologies for lesion detection, workflow optimization, quality control, and patient engagement—empowering clinicians with actionable insights and scalable solutions across the cancer care continuum. Lunit and Volpara also demonstrated the complementary value of combining Lunit INSIGHT Risk and Volpara Risk Pathways at RSNA 2024—offering a glimpse into how imaging-based and clinical data may be used together to personalize breast cancer risk assessment. The two solutions were shown as a prototype to work in tandem, that would predict the likelihood of breast cancer development within 1 to 5 years, to enable earlier interventions, more personalized care, and redefine standards for breast cancer screening and management. "The successful integration of Lunit and Volpara has accelerated our mission to transform cancer diagnostics globally, and the momentum we've built in the United States marks just the beginning," said Brandon Suh, CEO of Lunit. "By combining Lunit's AI innovation with Volpara's breast health expertise, we're delivering a new standard of comprehensive support for clinicians—enhancing early detection, improving screening quality, optimizing workflows, and ultimately helping providers deliver better outcomes for patients worldwide. With our expanded footprint and comprehensive ecosystem, we are poised to lead the future of cancer care." Lunit plans to further expand its U.S. operations, building on its strong foundation with next-generation AI solutions, dedicated clinical support, and a growing ecosystem designed to shape the future of cancer detection and care. About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics. Porton Advanced will provide end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, from process optimization to regulatory submission, accelerating its development progress. Hualong Biological 's research team has established a strong clinical foundation for its MATC platform through multiple investigator-initiated trials (IITs), demonstrating significant therapeutic benefits across various solid tumor indications. Porton Advanced will leverage its industry-leading process development platforms, GMP manufacturing capabilities, and proven regulatory expertise to optimize the MATC therapy's CMC strategy and facilitate its transition from research to clinical development. Mingguang Huang, Chairman of Hualong Biological, commented: "We are delighted to partner with Porton Advanced. Their comprehensive CDMO technical expertise and regulatory experience in cell therapy will significantly enhance our MATC program's development efficiency and IND preparation timeline. Together, we're committed to advancing this innovative therapy into clinical trials to benefit patients worldwide." Andrew Chen, CFO of Porton Advanced, stated: "Collaborating with Hualong Biological marks a strategic expansion of our CDMO services in cell therapy. We are honored to provide regulatory-compliant, high-quality MATC CMC services to support their IND application. Porton Advanced is committed to supporting partners through our integrated technology platform and regulatory experience to bring cutting-edge therapies to patients faster." About Hualong Biological Founded in 2012, Henan Hualong Biological is a national high-tech enterprise in China specializing in cell technology development and applications. Aligned with its strategic vision of integrating cell storage, research, therapeutic development, and clinical applications, Hualong Biological primarily focuses on cell banking, cell therapy development, and related cell technology services. The company has established advanced expertise in immune and stem cell technologies, with several core technical parameters ranking among industry leaders. Its comprehensive platform addresses the full spectrum of cell therapy development, from fundamental research to clinical implementation. Through continuous technological innovation and strategic market expansion, Hualong Biological has emerged as a leading cell therapy enterprise in Henan Province. The company remains committed to consolidating its influential position within the cellular technology industry. About Porton Advanced Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization. Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sqft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China. Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner. For more information about Porton Advanced, please visit: www.portonadvanced.com.
Live remote operation demo of humanoid robot RB-Y1 scheduled for May 20–22 First public unveiling of new Mecanum Wheel system, and an integrated SDK with various modular compatibility options ATLANTA, May 19, 2025 /PRNewswire/ -- Rainbow Robotics, a robotics platform company (CEO Jungho Lee) based in Korea, will showcase its latest advancements in humanoid robotics during the 2025 IEEE International Conference on Robotics and Automation (ICRA)—the world's largest robotics conference—taking place in Atlanta, USA, from May 19 to 23. The company will present innovative technologies that reflect its growing capabilities in next-generation humanoid robotic systems. Organized by the IEEE (Institute of Electrical and Electronics Engineers), ICRA is the world's largest robotics technology exhibition and academic event, drawing over 7,000 robotics researchers, professionals and leading companies from around the world each year. Following its debut of Korea's first mobile humanoid robot, RB-Y1, at ICRA 2024 in Yokohama, Japan, Rainbow Robotics will return to this year's conference with a dedicated exhibition booth (Georgia World Congress Center, Hall A #811) from May 20 to 22. The company will present live demonstrations of RB-Y1's real-time remote control and interactive features. On-site demonstrations will showcase multiple interactive control interfaces for RB-Y1, including: Master Arm Touchpad and joystick interface VR device-based control interface The RB-Y1 humanoid robot features dual 7-degree-of-freedom (DOF) arms, a 6-axis DOF single leg, and a wheel-based mobile platform. Designed to support a wide range of development environments, it provides open APIs and modular options, positioning it as a versatile research platform for AI and robotics software developers. Since its public debut in March 2024, RB-Y1 has received pre-orders from institutions worldwide and is currently being utilized by leading universities—including MIT, UC Berkeley, the University of Washington, and Georgia Tech—as well as companies across various industries. At ICRA 2025, Rainbow Robotics will unveil two major innovations: Mecanum Wheel System: A specialized omnidirectional wheel technology that allows 360-degree movement, significantly enhancing maneuverability in constrained spaces. Integrated RB-Y1 Software Development Kit (SDK): An integrated SDK compatible with various modules including IMU, gripper, and LiDAR, allowing easy customization to fit a wide range of research and development applications. Jungwoo Heo, CTO of Rainbow Robotics, commented, "Our humanoid robot is purpose-built for AI researchers and developers. As our message 'This is Your Humanoid, Make it Perfect for Your AI Solution' suggests, it is designed to offer a platform optimized for applying diverse AI technologies. With the unveiling of the Mecanum Wheel system and integrated SDK at ICRA 2025, we aim to establish Rainbow Robotics as a technology leader in the global humanoid robotics market." Ahead of ICRA 2025, Rainbow Robotics has also attracted significant attention in the U.S., with its promotional videos surpassing 2.47 million cumulative views on YouTube. The company is also actively expanding its local footprint through its U.S. subsidiary in Chicago, providing technical support and fostering collaborations with AI developers across the region.
NEW YORK, May 19, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on May 19th Moody's downgraded the U.S. credit rating from Aaa to Aa1, citing persistent federal deficits and the growing challenge of refinancing U.S. debt at higher interest rates, bringing the U.S. in line with other major economies. The downgrade is expected to push Treasury yields higher and bond prices lower, potentially impacting broader financial markets. President Trump has urged the Federal Reserve to cut interest rates, but Chair Jerome Powell has signaled a cautious, data-driven approach, with several Fed officials scheduled to speak ahead of the next rate decision on June 18. Opening Bell Universal Technical Institute, Inc. (NYSE:UTI) to ring The Opening Bell in celebration of their 60th anniversary and successful North Star strategy to define the future workforce. Closing Bell Northpointe Bancshares, Inc. (NYSE: NPB) to ring The Closing Bell® in celebration of their recent public offering. Download the NYSE TV App and Subscribe Here Video - https://mma.prnewswire.com/media/2690735/NYSE_Market_Update_May_19.mp4
TAIPEI, May 19, 2025 /PRNewswire/ -- Fibocom, a global leading provider of wireless communication modules and AI solutions, announces the launch of its 5G module FG390, developed on the advanced MediaTek T930 platform. Designed specifically for mobile broadband (MBB) terminal products focused on 5G Fixed Wireless Access (FWA), the FG390 series seeks to boost FWA industry growth across diverse applications such as CPEs, ODUs, mobile hotspot devices, enterprise gateways, and industrial gateways. FG390 is a highly integrated, high-performance 5G module built on MediaTek's advanced T930 chipset, featuring cutting-edge 4nm process technology. It incorporates the MediaTek M90 5G modem alongside a quad-core ARM Cortex-A55 CPU, delivering robust functionality and full compliance with 3GPP Release 18 standards. Supporting downlink 6-carrier aggregation (6CC CA) and uplink 5-layer 3Tx transmission within the 5G NR Sub-6GHz spectrum, the FG390 achieves peak standalone (SA) downlink speeds of up to 10 Gbps and uplink speeds reaching 2.8 Gbps, providing an outstanding high-speed 5G experience. Furthermore, with 200MHz bandwidth and 8Rx technology, the module significantly enhances spectrum efficiency about 40% at cell edges, greatly extending signal coverage. Paired with a dedicated NPU chip, the FG390 powers AI-enabled gateway devices to offer advanced, intelligent network interaction capabilities. Amid the swift convergence of 5G-A and AI technologies, the FG390 series harnesses cutting-edge specifications, innovative features, and a comprehensive suite of peripherals to drive digital transformation and continuous innovation across both residential and enterprise applications. This breakthrough empowers telecom operators and the broader market to enhance investment efficiency and accelerate returns in the communications terminal sector. Leveraged by the MediaTek T930 platform, the FG390 seamlessly integrates robust 5G Release 18 protocol capabilities with exceptional cellular performance and AI-driven intelligence, setting a new benchmark for the next generation of mobile broadband terminals. Enhanced by a dedicated NPU for AI acceleration, this module empowers transformative applications across smart offices, smart homes, and smart cities. Fibocom remains dedicated to deepening the collaboration with MediaTek to drive continuous innovation in 5G technologies, products, and ecosystem development.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
